To start your customized experience click the start button
Customize ?  
Cancer Types
Quick Links
Award Programs
About Us
Contact Us
Privacy Policy
Terms & Conditions
Face Book
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Liver Cancer

Danielle Bucco
After nearly a decade with no new therapies, new drugs to treat liver cancer are showing great promise, according to Steven R. Alberts, M.D.
Opdivo (nivolumab) was granted FDA approval for the treatment of hepatocellular carcinoma (HCC) – regardless of PD-L1 status – for patients who have previously been treated with Nexavar (sorafenib).
Andrea J. Wilson
Andrea J. Wilson, president and founder of Blue Faery: The Adrienne Wilson Liver Cancer Association, offers advice for patients with liver cancer. Wilson started the foundation after her younger sister, Adrienne, died of liver cancer.
Jason M. Broderick
Opdivo (nivolumab) was granted a priority review designation by the Food and Drug Administration (FDA) to treat some patients with liver cancer.
Jason M. Broderick
The Food and Drug Administration (FDA) has approved Stivarga as a second-line treatment for patients with unresectable hepatocellular carcinoma (HCC) who have previously received Nexavar.
Debu Tripathy, MD

Understanding liver cancer is a crucial step toward the prevention of this rare condition.

Liver cancer diagnoses and mortality have been rising, but new treatments are designed to help reverse the trend.
Jason M. Broderick
A recent phase 3 trial showed that treatment with Lenvima is noninferior to standard treatment for patients with unresectable liver cancer.
Jason M. Broderick
Stivarga was granted a priority review by the FDA to treat certain patients with liver cancer in the second line setting. 

Sign In

Not a member? Sign up now!
Continue without login

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment


Healthcare Professional

Not Applicable